|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
aurora B kinase is highly expressed in several cancer cells and promotes tumorigenesis and progression, and therefore, it is an important target for drug to treat tumors.
|
27704720 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Histone H3 phosphorylation precedes the induction of apoptosis in p53-/- tumour cell lines but does not appear to be required for this fate as an Aurora kinase inhibitor suppresses phosphorylation of both Aurora B and histone H3 but has little effect on cell death.
|
24853431 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, AURKB-Sv2 variant form is associated with a higher level of serum alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II (PIVKAII), tumor capsular invasion, multiple tumor formation and at an age younger than those with other variant forms (P < 0.05).
|
19134008 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analyzed Aurora B expression in gcGB (n = 28) and GB (n = 54) patient tumor samples by immunohistochemistry; 17 gcGB and 22 GB samples were analyzed at the DNA and mRNA levels.
|
20467329 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Neither baseline tumor expression of AURKA (ROC = 0.57, P = 0.46) nor AURKB (ROC = 0.56, P = 0.87) predicted for ypT2-4 status.
|
31597600 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, dual therapy with trastuzumab and lapatinib resulted in significant antitumor activity only in ARK2 and EnCa1 tumors.
|
25294905 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with peripheral T-cell lymphoma, not otherwise specified and normal γδ T cells, HSTL overexpressed genes encoding NK-cell-associated molecules, oncogenes (FOS and VAV3), the sphingosine-1-phosphatase receptor 5 involved in cell trafficking, and the tyrosine kinase SYK, whereas the tumor-suppressor gene AIM1 (absent in melanoma 1) was among the most down-expressed.
|
22510872 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, aurora B was positively related to grading and tumor size and negatively to differentiation and functionality.
|
29970506 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Univariate, multivariate and Kaplan-Mayer analyses documented the lack of association between Aurora-A or Aurora-B expression and clinicopathological parameters such as gender, age, tumor size, histology, TNM stage, lymph node metastasis and BRAF status as well as disease recurrences or disease-free interval.
|
25807528 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, sustained expression of Aurora-B induces tetraploidy, which, in turn, facilitates genomic instability and tumor development in a xenograft model.
|
19332642 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aurora B expression in tumor and non-tumor tissue was examined by use of quantitative reverse transcription-polymerase chain reaction.
|
23893130 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that AURKA and AURKB overexpression in pediatric ACT may be related to more aggressive disease and the inhibition of these proteins could be an interesting approach for the treatment of these tumors.
|
23788275 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated the effects of the bona fide Aurora-B kinase inhibitor AZD1152 on tumor responses to ionizing radiation (IR).
|
18084327 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Informative TMA results were obtained in 91 tumor cases for Aurora-B and 93 tumor cases for FOXM1.
|
25986250 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SIX3 is a novel negative transcriptional regulator and acts as a tumor suppressor that directly represses the transcription of AURKA and AURKB in astrocytoma.
|
28595628 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knocking down of Aurora B with shRNA substantially inhibited HCC cell proliferation, colony formation and delayed tumor growth in nude mice.
|
30263005 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytosolic staining intensity of the ARK2 protein was associated with tumor stage (p = 0.006) and tumor size (T) of TNM staging system (p = 0.026).
|
23504335 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, we found that the tumor suppressive effect of Aurora-B and HDAC inhibition is due to the induction of cell cycle arrest and/or apoptosis.
|
26638998 |
2016 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
LINE-1 hypomethylation and AIM1 hypermethylation have prognostic utility in both melanoma patients' tumors and serum.
|
22402438 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromosome instability in tumor cells due to defects in Aurora B mediated error correction at kinetochores.
|
30513041 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor growth was significantly lower in AKB-LfNPs alone and in combination with TMZ treated mice and increased the survival by 2.5-times.
|
30334671 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GSK1070916 is a potent, selective, ATP competitive inhibitor of Aurora kinase B and C. Translation of predictive biomarkers to the clinic can benefit patients by identifying the tumors that are more likely to respond to therapies, especially novel inhibitors such as GSK1070916.
|
21762492 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bub1 overexpression induces aneuploidy and tumor formation through Aurora B kinase hyperactivation.
|
21646403 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aurora B overexpression is an independent molecular marker predicting tumor invasiveness and poor prognosis of HCC.
|
20799978 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Involvement of aurora kinase B (AURKB) and Wee1-like protein kinase (WEE1) as downstream proteins in the (V600E)B-RAF pathway was validated in xenografted tumors, and mechanisms of action were characterized in size- and time-matched tumors.
|
23416158 |
2013 |